vs
Side-by-side financial comparison of McDonald's (MCD) and Viatris (VTRS). Click either name above to swap in a different company.
McDonald's is the larger business by last-quarter revenue ($7.0B vs $3.7B, roughly 1.9× Viatris). On growth, McDonald's posted the faster year-over-year revenue change (9.7% vs 5.0%). McDonald's produced more free cash flow last quarter ($1.6B vs $619.3M). Over the past eight quarters, McDonald's's revenue compounded faster (6.6% CAGR vs 0.5%).
McDonald's Corporation, doing business as McDonald's, is an American multinational fast food restaurant chain. As of 2024, it is the second-largest by number of locations in the world, behind the Chinese chain Mixue Ice Cream & Tea.
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
MCD vs VTRS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $7.0B | $3.7B |
| Net Profit | $2.2B | — |
| Gross Margin | — | 31.1% |
| Operating Margin | 45.0% | -5.2% |
| Net Margin | 30.9% | — |
| Revenue YoY | 9.7% | 5.0% |
| Net Profit YoY | 7.3% | — |
| EPS (diluted) | $3.03 | $-0.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $7.0B | $3.7B | ||
| Q3 25 | $7.1B | $3.7B | ||
| Q2 25 | $6.8B | $3.6B | ||
| Q1 25 | $6.0B | $3.2B | ||
| Q4 24 | $6.4B | $3.5B | ||
| Q3 24 | $6.9B | $3.7B | ||
| Q2 24 | $6.5B | $3.8B | ||
| Q1 24 | $6.2B | $3.7B |
| Q4 25 | $2.2B | — | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $1.9B | — | ||
| Q4 24 | $2.0B | — | ||
| Q3 24 | $2.3B | — | ||
| Q2 24 | $2.0B | — | ||
| Q1 24 | $1.9B | — |
| Q4 25 | — | 31.1% | ||
| Q3 25 | 90.6% | 36.6% | ||
| Q2 25 | 90.4% | 37.3% | ||
| Q1 25 | 89.6% | 35.8% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | 90.6% | 39.0% | ||
| Q2 24 | 90.3% | 38.2% | ||
| Q1 24 | 89.8% | 41.2% |
| Q4 25 | 45.0% | -5.2% | ||
| Q3 25 | 47.4% | 4.8% | ||
| Q2 25 | 47.2% | 6.5% | ||
| Q1 25 | 44.5% | -88.9% | ||
| Q4 24 | 44.9% | -5.1% | ||
| Q3 24 | 46.4% | 6.0% | ||
| Q2 24 | 45.0% | -6.3% | ||
| Q1 24 | 44.4% | 5.6% |
| Q4 25 | 30.9% | — | ||
| Q3 25 | 32.2% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 31.4% | — | ||
| Q4 24 | 31.6% | — | ||
| Q3 24 | 32.8% | — | ||
| Q2 24 | 31.2% | — | ||
| Q1 24 | 31.3% | — |
| Q4 25 | $3.03 | $-0.34 | ||
| Q3 25 | $3.18 | $-0.11 | ||
| Q2 25 | $3.14 | $0.00 | ||
| Q1 25 | $2.60 | $-2.55 | ||
| Q4 24 | $2.80 | $-0.43 | ||
| Q3 24 | $3.13 | $0.08 | ||
| Q2 24 | $2.80 | $-0.27 | ||
| Q1 24 | $2.66 | $0.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $774.0M | $1.3B |
| Total DebtLower is stronger | $40.0B | — |
| Stockholders' EquityBook value | $-1.8B | $14.7B |
| Total Assets | $59.5B | $37.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $774.0M | $1.3B | ||
| Q3 25 | $2.4B | $975.3M | ||
| Q2 25 | $1.9B | $566.4M | ||
| Q1 25 | $1.2B | $755.0M | ||
| Q4 24 | $1.1B | $734.8M | ||
| Q3 24 | $1.2B | $1.9B | ||
| Q2 24 | $792.0M | $917.2M | ||
| Q1 24 | $838.0M | $1.0B |
| Q4 25 | $40.0B | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $38.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $-1.8B | $14.7B | ||
| Q3 25 | $-2.2B | $15.2B | ||
| Q2 25 | $-2.8B | $15.6B | ||
| Q1 25 | $-3.5B | $15.7B | ||
| Q4 24 | $-3.8B | $18.6B | ||
| Q3 24 | $-5.2B | $19.8B | ||
| Q2 24 | $-4.8B | $19.5B | ||
| Q1 24 | $-4.8B | $20.0B |
| Q4 25 | $59.5B | $37.2B | ||
| Q3 25 | $60.6B | $37.9B | ||
| Q2 25 | $59.6B | $38.4B | ||
| Q1 25 | $56.3B | $38.5B | ||
| Q4 24 | $55.2B | $41.5B | ||
| Q3 24 | $56.2B | $44.8B | ||
| Q2 24 | $53.8B | $45.3B | ||
| Q1 24 | $53.5B | $47.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $2.7B | $815.8M |
| Free Cash FlowOCF − Capex | $1.6B | $619.3M |
| FCF MarginFCF / Revenue | 23.4% | 16.8% |
| Capex IntensityCapex / Revenue | 15.1% | 5.3% |
| Cash ConversionOCF / Net Profit | 1.25× | — |
| TTM Free Cash FlowTrailing 4 quarters | $7.2B | $1.9B |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.7B | $815.8M | ||
| Q3 25 | $3.4B | $744.9M | ||
| Q2 25 | $2.0B | $219.7M | ||
| Q1 25 | $2.4B | $535.5M | ||
| Q4 24 | $2.6B | $482.7M | ||
| Q3 24 | $2.7B | $826.5M | ||
| Q2 24 | $1.7B | $379.1M | ||
| Q1 24 | $2.4B | $614.6M |
| Q4 25 | $1.6B | $619.3M | ||
| Q3 25 | $2.4B | $658.1M | ||
| Q2 25 | $1.3B | $166.8M | ||
| Q1 25 | $1.9B | $492.9M | ||
| Q4 24 | $1.8B | $342.3M | ||
| Q3 24 | $1.9B | $749.5M | ||
| Q2 24 | $1.1B | $320.3M | ||
| Q1 24 | $1.8B | $564.8M |
| Q4 25 | 23.4% | 16.8% | ||
| Q3 25 | 34.1% | 17.6% | ||
| Q2 25 | 18.3% | 4.7% | ||
| Q1 25 | 31.5% | 15.2% | ||
| Q4 24 | 28.6% | 9.7% | ||
| Q3 24 | 28.3% | 20.1% | ||
| Q2 24 | 16.3% | 8.5% | ||
| Q1 24 | 29.9% | 15.5% |
| Q4 25 | 15.1% | 5.3% | ||
| Q3 25 | 14.3% | 2.3% | ||
| Q2 25 | 10.9% | 1.5% | ||
| Q1 25 | 9.3% | 1.3% | ||
| Q4 24 | 12.6% | 4.0% | ||
| Q3 24 | 11.6% | 2.1% | ||
| Q2 24 | 9.7% | 1.6% | ||
| Q1 24 | 8.9% | 1.4% |
| Q4 25 | 1.25× | — | ||
| Q3 25 | 1.50× | — | ||
| Q2 25 | 0.89× | — | ||
| Q1 25 | 1.30× | — | ||
| Q4 24 | 1.30× | — | ||
| Q3 24 | 1.21× | — | ||
| Q2 24 | 0.84× | — | ||
| Q1 24 | 1.24× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
MCD
| International Operated Markets | $3.6B | 51% |
| Other | $2.8B | 40% |
| International Developmental Licensed Marketsand Corporate | $633.0M | 9% |
VTRS
| Brands | $1.2B | 32% |
| Generics | $1.1B | 29% |
| Lipitor | $377.3M | 10% |
| Norvasc | $175.2M | 5% |
| Other | $136.6M | 4% |
| Lyrica | $119.8M | 3% |
| Viagra | $104.2M | 3% |
| Creon | $98.9M | 3% |
| Epi Pen Auto Injectors | $79.0M | 2% |
| Yupelri | $70.6M | 2% |
| Effexor | $68.1M | 2% |
| Zoloft | $66.8M | 2% |
| Celebrex | $66.2M | 2% |
| Xalabrands | $42.0M | 1% |
| Dymista | $38.6M | 1% |
